Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Lipocine宣佈確認LPCN 1154關鍵研究的給藥方案
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study
On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing
積極的臨床研究結果證實了這項關鍵 PK 研究的 48 小時給藥方案
Q2-24 關鍵研究結果和計劃中的 Q4-24 保密協議申請已步入正軌
SALT LAKE CITY, Feb. 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic (PK) study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression (PPD).
鹽湖城,2024年2月6日 /PRNewswire/ — 專注於利用其專有平台治療中樞神經系統(CNS)疾病的生物製藥公司Lipocine Inc.(納斯達克股票代碼:LPCN)今天宣佈,一項多劑量臨床研究的結果證實了即將到來的NDA的關鍵藥代動力學(PK)研究的LPCN 1154 48小時給藥方案。LPCN 1154是Lipocine正在開發的一種口服神經類固醇,用於治療產後抑鬱症(PPD)。
PPD is a major depressive disorder with onset either...
PPD 是一種嚴重...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。